Odne completes successful financing for US market expansion

Odne

Wed. 18. June 2025

save

DÜBENDORF, Switzerland: Swiss dental innovator Odne has announced the closing of a successful financing round, having raised CHF 4.2 million (€4.5 million*) to fund its US market expansion. In addition to existing investors and employees, this financing round was supported by ZEISS Ventures, as well as a group of private and dental investors.

Odne’s innovative platform for Root Preservation Therapy (RPT) is expected to transform endodontics. A key device within this platform is OdneClean, a hydro-dynamic cavitation device using sterile water as the main debridement medium, which received FDA clearance in August 2024. Odne successfully ran a priority access program and launched OdneClean to the endodontic community at AAE 2025 in Boston. The other two devices making up the RPT platform are OdneFill, a highly flowable all-in-one obturation material, and OdneCure, the thinnest micro-laser for light-curing. OdneFill and OdneCure both received FDA clearance in 2023 and their joint priority access program which began in May 2024 is currently being continued.

Speaking on the clinical significance of this suite of products, Dr Andreas Schmocker, CEO and co-founder of Odne, stated: “It is amazing to see the positive response of the endodontic community to OdneClean. It is an affordable, high-tech solution for debridement and disinfection of the root canal—efficiently cleaning complex root canal geometries and de-risking and accelerating procedures. The solution addresses a wide range of clinical challenges and serves as an easy-to-use, essential device for any dentist. We expect that the complete Odne RPT workflow, enabling minimally invasive treatment, combining advanced irrigation with sterile water and simple light-cured obturation of complex root morphologies, will become the new gold-standard.”

Echoing these thoughts, Dr Boris Hofmann, head of ZEISS Ventures, expressed: “We strongly believe that Odne’s RPT workflow has the potential to fundamentally transform endodontic treatment, benefiting both specialised endodontists and general practitioners.”

Editorial note:

* Calculated on the OANDA platform for 12 June 2025.